Bellicum Pharmaceuticals, Inc. (BLCM) Stock Price, Financial Report, & Fundamental Analysis
NASDAQ:BLCMBellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens.
(0.9)
Bellicum Pharmaceuticals, Inc. Fundamental Analysis
Strength
| Analysis | # |
|---|---|
Revenue GrowthBLCM has had growing revenue for the last 2 years |
|
RevenueBLCM has positive revenue for last 5 years |
Weakness
| Analysis | # |
|---|---|
Market CapSmall market capitalization. Market capitalization is less than 2bn USD |
|
Net Income GrowthBLCM has never had growing net income. |
|
Price to Book (PBV) RatioOvervalued price-to-book. BLCM stock price is overvalued by more than 2x the price-to-book value. |
|
Net IncomeBLCM never has positive net income for 2 years. |
|
Debt-Equity Ratio (DER)BLCM debt is 3.17x it's equity. |
|
Dividend YieldBLCM has low dividend yield (0%). |
|
Return of AssetsBLCM has low return of asset (-20.94%). |
|
Return of EquityBLCM has low return of equity (-41.35%). |
|
Return of Invested CapitalBLCM has low ROIC. |
Competitors
Bellicum Pharmaceuticals, Inc. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Income Statement
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- Revenue
- 6,200 USD
- Cost
- 0 USD
- Net Income
- -9,705 USD
- Profit Margin
- -156.53%
Cashflow Statement
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -22,206 USD
Balance Sheet
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
| Quick Ratio | 517.68% |
Long Term Liabilities
| Liquidity/Current Ratio | 543.95% |
Dividend
| Dividend Yield | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend per Share | 0,00 USD |
Financial Ratios
| Price to Earning (PER) | 5.4x |
| Price to Earning-Growth (PEG) | 0x |
| Price to Book Value (PBV) | 0x |
| Liquidity/Current Ratio | 543.95% |
| Cash Ratio | 500.28% |
| Debt Ratio | 76.03% |
| Debt-Equity Ratio (DER) | 317.16% |
| Net Profit Margin (NPM) | 139.54% |
| Return of Assets (ROA) | -20.94% |
| Return of Equity (ROE) | -41.35% |
| Return on Capital Employed (ROCE) | -96.89% |
| Days of Sales Outstanding (DSO) | -77.76 |
| Days of Inventory Outstanding (DIO) | 0 |
| Days Payable Outstanding (DPO) | 0 |
| Operating Cycle (OC) | 0 |
| Cash Conversion Cycle (CCC) | 0 |
Bellicum Pharmaceuticals, Inc. Executives
CEO
- CEO Name
- Mr. Richard Fair
Management
Bellicum Pharmaceuticals, Inc. Profile
About Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
Additional Information
- Company name
- Bellicum Pharmaceuticals, Inc.
- Symbol
- NASDAQ:BLCM
- Exchange
- NASDAQ Capital Market
- Industry
- Biotechnology
- Sector
- Healthcare
- Address
-
2130 W Holcombe Blvd Ste 800
Houston
TEXAS
US
77098 - Website
- https://www.bellicum.com